Peramivir and laninamivir susceptibility of circulating influenza A and B viruses

Influenza and other Respiratory Viruses

Volumn 8, Issue 2, 2014, Pages 135-139

  Leang, Sook Kwan ^a   Kwok, Simon ^a   Sullivan, Sheena G ^a   Maurer Stroh, Sebastian ^b,c,d   Kelso, Anne ^a   Barr, Ian G ^a,e   Hurt, Aeron C ^a,e  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b BIOINFORMATICS INSTITUTE   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d MINISTRY OF HEALTH   (Singapore)

^e UNIVERSITY OF BALLARAT   (Australia)

Author keywords

Antiviral susceptibility; Laninamivir; Neuraminidase inhibitors; Peramivir

Indexed keywords

AFRICA; ANTIVIRAL AGENTS; ASIA; CYCLOPENTANES; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; JAPAN; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; NEURAMINIDASE; OCEANIA; VIRAL PROTEINS; ZANAMIVIR;

EID: 84894475774     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12187     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians, 2012. Available at http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed 22 May 2013).
2. Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther 2012; 10:123-143.
3. BioCryst Pharmaceuticals I. Peramivir (Neuraminidase Inhibitor), 2013. Available at http://www.biocryst.com/peramivir (Accessed 22 May 2013).
4. ChinaBioToday. China's SFDA ready to fast-track approvals of peramivir, a flu treatment, 2013. Available at http://www.chinabiotoday.com/articles/20130408_1 (Accessed 22 May 2013).
5. Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361:2204-2207.
6. Koyama K, Takahashi M, Oitate M et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother 2009; 53:4845-4851.
7. Ishizuka H, Yoshiba S, Yoshihara K, Okabe H. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958. J Clin Pharmacol 2011; 51:243-251.
8. IMSHealth. Available at www.imshealth.com/ (Accessed 18 April 2013).
9. Dapat C, Kondo H, Dapat IC et al. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. Antiviral Res 2013; 99:261-269.
10. Takashita E, Fujisaki S, Kishida N et al. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan. Influenza Other Respir Viruses 2013; doi: 10.1111/irv.12132. [Epub ahead of print].
11. Okomo-Adhiambo M, Sleeman K, Lysen C et al. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir Viruses 2013; 7:645-658.
12. Meijer A, Lackenby A, Hungnes O et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552-560.
13. Hurt AC, Ernest J, Deng YM et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 83:90-93.
14. Hurt AC, Okomo-Adhiambo M, Gubareva LV. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods Mol Biol 2012; 865:115-125.
15. WHO. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012; 39:369-374.
16. Hurt AC, Hardie K, Wilson NJ et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365:2541-2542.
17. Leang SK, Deng YM, Shaw R et al. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res 2013; 97:206-210.
18. Wang D, Sleeman K, Huang W et al. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antiviral Res 2013; 97:240-244.
19. Sleeman K, Sheu TG, Moore Z et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerg Infect Dis 2011; 17:2043-2046.
20. Okomo-Adhiambo M, Nguyen HT, Sleeman K et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res 2010; 85:381-388.
21. FDA. Emergency use authorization of peramivir IV fact sheet for health care providers November 2009. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf (Accessed 07 August 2013).
22. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252-1255.